scholarly journals Neurocysticercosis presenting as bipolar disorder: a case report

2021 ◽  
Vol 34 (6) ◽  
pp. e100663
Author(s):  
Surbhi Batra ◽  
Sumit Kumar ◽  
Lokesh Singh Shekhawat
Keyword(s):  
Bipolar Disorder ◽  
Case Report ◽  
Depressive Symptoms ◽  
Affective Disorder ◽  
Postpartum Period ◽  
Bipolar Affective Disorder ◽  
Taenia Solium ◽  
Manic Episode ◽  
Symptoms And Signs ◽  
Rule Out

Neurocysticercosis is the most common neuro-parasitosis caused by the larval stage of Taenia solium. The most common manifestations include seizures and hydrocephalus. Psychiatric abnormalities are relatively rare but depressive symptoms are frequent in patients with neurocysticercosis. However, mania as a presentation is relatively rare. Pregnancy and the postpartum period are relatively vulnerable times and they can lead to reactivation of existing neurocysterci lesions. We are discussing the case of a 23-year-old female patient with neurocysticercosis leading to the reactivation of lesions in the peripartum and postpartum period leading to bipolar affective disorder. Improvement in the patient was seen with a combination of antipsychotics, antihelmintics, antiepileptics and steroids, along with improved radiological signs of neurocysterci lesions. Although neurocysticercosis is a common illness, its prevalence presenting as a manic episode is merely 2.6% and, hence, missed easily. Therefore, it is important to rule out organic aetiology in patients even with a classic presentation of bipolar affective disorder and those having any other neurological symptoms and signs.

A Retrospective Case-Note Study of Bipolar Disorder in Old Age

1991 ◽  
Vol 158 (4) ◽  
pp. 485-490 ◽  
Author(s):  
John Snowdon
Keyword(s):  
Bipolar Disorder ◽  
Affective Disorder ◽  
Age Of Onset ◽  
Bipolar Affective Disorder ◽  
Manic Episode ◽  
Case Note ◽  
Retrospective Case ◽  
History Of ◽  
Study Case ◽  
Reason For Admission

In a replication of an earlier published study, case notes of 75 elderly in-patients with bipolar affective disorder were examined. Few of the patients had experienced a manic episode before the age of 40. Mean age of onset of affective disorder was 46 years, and first manic episode at 60 years. Cerebral insults before the first manic attacks were recorded in a substantial number of cases, and a family history of mental illness was less common among this group. Bipolar affective disorder is relatively common as a reason for admission of elderly patients.

Hydrocephalus and bipolar affective disorder

2011 ◽  
Vol 28 (4) ◽  
pp. 222-223
Author(s):  
Syed Naveed Asif Rizvi ◽  
Marie Whitty ◽  
Robert Daly
Keyword(s):  
Bipolar Disorder ◽  
Depressive Symptoms ◽  
Affective Disorder ◽  
Late Onset ◽  
Bipolar Affective Disorder ◽  
Rapid Cycling ◽  
Brain Pathology ◽  
Treatment Resistant ◽  
Bipolar Illness ◽  
Organic Brain

AbstractBipolar disorder can emerge in the context of organic brain pathology. In the case presented, long-standing hydrocephalus was diagnosed in a man with relatively late-onset bipolar illness who presented initially with somewhat atypical, treatment-resistant depressive symptoms. Hypomania, followed by a rapid-cycling bipolar course, subsequently developed. This report reviews the association between bipolar disorder and hydrocephalus, and examines possible neurobiological mechanisms implicated in both conditions.

A Case Report of a Woman with Premenstrual Dysphoric Disorder Misdiagnosed as Having Bipolar Affective Disorder

2020 ◽  
Vol 13 (2) ◽  
pp. 144-146
Author(s):  
Rossitza K. Iakimova ◽  
Maya Y. Stoimenova-Popova ◽  
Petranka G. Chumpalova ◽  
Milena S. Pandova ◽  
Maria B. Stoyanova
Keyword(s):  
Bipolar Disorder ◽  
Differential Diagnosis ◽  
Case Report ◽  
Affective Disorder ◽  
Bipolar Affective Disorder ◽  
Correct Diagnosis ◽  
Premenstrual Dysphoric Disorder ◽  
Mood Changes ◽  
Affective Symptoms

Summary Frequent mood changes are found in premenstrual dysphoric disorder (PMDD) as well as in bipolar affective disorder (BAD). The differential diagnosis is difficult because both conditions share some other common symptoms. We present a case study of a woman with premenstrual dysphoric disorder misdiagnosed as bipolar disorder. As a result, the patient was prescribed lithium and remained symptomatic for a prolonged period. She recovered only after initiation of treatment with a selective serotonin reuptake inhibitor, which is the treatment of choice in the management of PMDD. In such cases, the importance of affective symptoms evaluation is underscored in the context of the menstrual cycle, as well as in recognizing them for the correct diagnosis and treatment.

scholarly journals Analisis Efektivitas Biaya Terapi Kombinasi Mood Stabilizer dan Antipsikotik pada Pasien Gangguan Afektif Bipolar di Rawat Inap RSJ Grhasia Yogyakarta

2021 ◽  
Vol 6 (2) ◽  
pp. 210-216
Author(s):  
Novi Milasari ◽  
Dyah Aryani Perwitasari ◽  
Sawitri Sawitri
Keyword(s):  
Bipolar Disorder ◽  
Direct Medical Cost ◽  
Affective Disorder ◽  
Medical Cost ◽  
Average Length ◽  
Bipolar Affective Disorder ◽  
Mood Stabilizer ◽  
Manic Episode ◽  
Mood Stabilizers ◽  
Antipsychotic Therapy

Bipolar affective disorder is an episodic mental disorder characterized by manic, hypomanic, depressive, and mixed episodes, usually recurring and can last a lifetime. Patients with bipolar disorder have annual medical costs that were four times those of patients without bipolar disorder. The aim of this study is to analyze the cost-effectiveness of combination therapy between mood stabilizers and antipsychotics in patients with the bipolar affective disorder at Grhasia Mental Hospital Yogyakarta. This study is a retrospective with cohort study design using medical records and direct medical cost data during Januari-December 2018 period. Subjects are patients who were diagnosed with bipolar affective disorder manic episode (F31.2) and received a combination of mood stabilizer and antipsychotic therapy. The results were obtained in 46 patients with the affective disorder who met the inclusion criteria. The average direct medical cost of the sodium divalproate group was IDR 6.319.933 per day and in the lithium group was IDR 5.705.953 per day. The average length of stay in the sodium divalproate group was 25,79 days and in the lithium group was 25,75 days (P = 0,991). The Average Cost Effectivity Ratio (ACER) sodium divalproat group is lower than the lithium group (IDR 221.246 per day and IDR 245.434 per day, respectively). The conclusion of this study is that the combination of sodium divalproate-antipsychotic therapy is more cost-effective than lithium-antipsychotic therapy in a patient with bipolar affective disorder manic episode

Mania with Bupropion: A Dose-Related Phenomenon?

2000 ◽  
Vol 34 (5) ◽  
pp. 619-621 ◽  
Author(s):  
Jessica L Goren ◽  
Gary M Levin
Keyword(s):  
Affective Disorder ◽  
Bipolar Depression ◽  
Bipolar Affective Disorder ◽  
Antidepressant Drug ◽  
Manic Episode ◽  
Total Daily Dose ◽  
High Dose ◽  
Related Phenomenon ◽  
Increased Risk ◽  
Daily Dose

OBJECTIVE: To report a case in which bipolar depression was resistant to usual therapies, requiring dosages of bupropion >450 mg/d and to review the literature on mania associated with bupropion and propose a potential theory of a dose-related threshold associated with bupropion and mania. CASE SUMMARY: A 44-year-old white man with a 25-year history of bipolar affective disorder presented with depression resistant to usual therapies. Bupropion therapy was initiated and the dosage was titrated to 600 mg/d. After exceeding the maximum recommended daily dose (450 mg/d), he experienced a manic episode attrib uted to high-dose bupropion. DISCUSSION: Due to increased risk of seizures, current prescribing guidelines state that the total daily dose of bupropion is not to exceed 450 mg/d. Since bupropion is the agent least likely to cause a manic switch in bipolar disorder, this agent seemed a logical choice to treat the patient's depression. Due to a lack of response, the bupropion dosage was titrated to a maximum of 600 mg/d. Since the patient did not switch into mania until the dosage exceeded 450 mg/d, we speculate that this adverse reaction is a dose-related phenomenon. Scientific literature supports this theory. CONCLUSIONS: A switch into mania is a potential risk associated with antidepressant drug use in bipolar affective disorder. Bupropion is believed to be associated with a decreased risk compared with other antidepressant therapies. However, our case report as well as others support the theory that this decreased risk may be due to dosages not exceeding the recommended daily dose (450 mg/d). Doses of bupropion >450 mg/d should be used with caution in depressed patients with bipolar affective disorder.

Lithium use in a patient on haemodialysis with bipolar affective disorder and lithium-induced nephropathy

2021 ◽  
Vol 14 (7) ◽  
pp. e242841
Author(s):  
Sam Topp ◽  
Emma Salisbury
Keyword(s):  
Affective Disorder ◽  
Bipolar Affective Disorder ◽  
Manic Episode ◽  
Dose Titration ◽  
Dialysis Session ◽  
Treatment Resistant ◽  
History Of ◽  
End Stage ◽  
Level Monitoring

Lithium is an effective mood stabiliser used to treat bipolar affective disorder (BPAD); however, it can also adversely affect the kidneys, causing acute toxic effects, nephrogenic diabetes insipidus, chronic renal dysfunction and end-stage kidney disease (ESKD) in a minority of patients. We describe the case of a man with a 34-year history of BPAD type-1 and a 2-year history of ESKD secondary to lithium-induced nephropathy who experienced a manic relapse. He previously responded well to lithium but, following a deterioration in kidney function, was switched to olanzapine and sodium valproate. This precipitated a period of instability, which culminated in a treatment-resistant manic episode requiring hospital admission. After a multidisciplinary team discussion, lithium therapy was restarted and provided remission. This was achieved safely through a reduced dosing schedule of three times a week post dialysis, slow dose titration and blood level monitoring prior to each dialysis session.

Mucopolysacharidosis Type I Presenting as Bipolar Affective Disorder: A Case Report

2021 ◽  
Vol 69 (6) ◽  
pp. 1753
Author(s):  
SapnaErat Sreedharan ◽  
UditU Saraf ◽  
Jithu Jose ◽  
Syam Krishnan
Keyword(s):  
Case Report ◽  
Affective Disorder ◽  
Bipolar Affective Disorder ◽  
Type I

scholarly journals Fahr’s Disease Presenting as Bipolar Affective Disorder - Case Report

2017 ◽  
Vol 03 (01) ◽  
Author(s):  
Vutova V ◽  
Popov L ◽  
Zlatareva D ◽  
Tacheva S ◽  
Vladimirova R ◽  
...  
Keyword(s):  
Case Report ◽  
Affective Disorder ◽  
Bipolar Affective Disorder ◽  
Fahr’S Disease ◽  
Fahr's Disease

Neuroleptic Malignant Syndrome and Risperidone: A Case Report

1996 ◽  
Vol 30 (3) ◽  
pp. 419-421 ◽  
Author(s):  
Richard J. Bonwick ◽  
Malcolm J. Hopwood ◽  
Philip L.R Morris
Keyword(s):  
Elderly Patient ◽  
Case Report ◽  
Affective Disorder ◽  
Neuroleptic Malignant Syndrome ◽  
Clinical Picture ◽  
Bipolar Affective Disorder

Objective: To describe a case of neuroleptic malignant syndrome associated with risperidone. Clinical picture: An elderly patient with bipolar affective disorder presented with neuroleptic malignant syndrome and relapse of hypomania after commencing risperidone. Treatment: Risperidone was ceased and the patient monitored closely. Outcome: The symptoms of neuroleptic malignant syndrome were resolved. Conclusion: To our knowledge this is the first such case reported, and suggests that risperidone, like other neuroleptics, is associated with neuroleptic malignant syndrome.

Sign in / Sign up

Export Citation Format

Share Document